Please join ‘EMA Transparency Initiative’

- A mass public request for EMA to release key information on the residual DNA present in modified mRNA vaccines.
- Submit this request on **Saturday 15th February 2025**.
- Any European resident can participate.
- Please ensure that you follow up when EMA replies as they will send out the documents via a link.

What to do

1. Go to **https://www.ema.europa.eu/en/about-us/contacts-european-medicines-agency/send-question-european-medicines-agency**
2. Fill out the online form according to the following:



3. **Copy & paste this text into the online form:**

I hereby formally request the immediate and unredacted disclosure of the Common Technical Document Modules for Comirnaty and Spikevax, along with substantial additional data regarding the Critical Quality Attributes (CQAs). All documents must be provided in their most current and officially active version at the time of release. Priority in disclosure should follow this ranking: 1.) qPCR Assay for residual DNA measurement, or any other methods applied to quantify residual DNA for Comirnaty as outlined in Procedure EMEA/H/C/005735/II/0202, 29 February 2024, including full data from the 236-batch analysis to validate the analysis submitted to EMA and Spikevax. 2.) CTD Module 2 and 3, particularly regarding CQA (specifications, acceptance criteria, control procedures and analytical results regarding RNA integrity, dsRNA content, residual DNA levels, RNA sequence identity, RNA concentration, bioburden, pH balance, 5 ′-CAP structure, and Poly(A) tail composition) for Comirnaty and Spikevax. With regard to Comirnaty Modules 3.2.S.2 (Manufacture) and 3.2.S.3 (Characterisation), please be aware of the re-release under ASK-257127. 3.) CTD Modules 4 and 5 for Comirnaty and Spikevax. This request is warranted by an overriding public interest, supported by publicly available evidence suggesting potential risks to human health. Numerous organizations across Europe are actively participating in this urgent appeal and will further substantiate the available evidence of potential harm, reinforcing the need for full disclosure of these critical safety data. Moreover, the undersigned would like to assert the prevailing public interest with regard to the pending case T-623/22, concerning Comirnaty's Specific Obligation Number 1 and CTD Module 3.2.S.3, is currently before the European Court for the unlawful withholding of safety relevant CQA data by EMA and BioNTech under the pretext of Confidential Commercial Information (CCI). As these data are integral to regulatory safety assessments, they do not qualify for CCI protections and must be disclosed under the overriding public interest principle established in EU jurisprudence.

4. You will receive an email confirmation from EMA with an individual ASK-Number in the subject line. Check you spam folder if you don't receive a response from EMA.
5. **IMPORTANT**: Please forward this email to **askEMA@NORTHgroup.info**
6. That's it – you are part of an historic mass action demanding transparency from the regulator of medical products in the EU.
7. Please share this info but only via email, Telegram, WhatsApp, or Signal – NOT via other social media channels to minimize the risk of EMA closing the web portal.

Thanks for joining the EMA Transparency Initiative!

We will be in touch via email when we receive a reply form EMA and by taking part you consent to allow us to contact you via email about this initiative. If you no longer wish to be contacted by NORTH Group please email notify us at **askEMA@NORTHgroup.info**.